Quantcast

Latest Isis Stories

2014-03-31 12:28:11

- Reductions of up to 64 percent in triglycerides achieved CARLSBAD, Calif., March 31, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIII(Rx) in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIII(Rx) achieved average reductions of up to 71 percent in apolipoprotein C-III (apoC-III) and up to 64 percent in triglycerides, and...

2014-03-24 08:27:25

Data to be presented in April at the European Association for the Study of the Liver Meeting CARLSBAD, Calif., March 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that treatment with an antisense compound targeting hepatitis B virus (HBV) produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection. These data will be presented at the 49(th) annual meeting of the European...

2014-03-19 08:28:25

CARLSBAD, Calif., March 19, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-ANGPTL3(Rx), an antisense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease. ISIS-ANGPTL3(Rx) is designed to act as a broad dyslipidemia agent. By reducing ANGPTL3, ISIS-ANGPTL3(Rx) has the potential to reduce LDL-cholesterol and triglycerides, and to increase...

2014-03-06 08:30:03

CARLSBAD, Calif., March 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 9:00 a.m. ET in Miami, FL. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...

2014-03-03 08:30:46

CARLSBAD, Calif., March 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of an open-label extension study of ISIS-TTR(Rx), which is being offered to those patients with familial amyloid polyneuropathy (FAP) who have completed dosing in the Phase 2/3 study of ISIS-TTR(Rx). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO ISIS-TTR(Rx) is...

2014-02-28 08:25:30

- Outperforms 2013 Projections for Pro Forma Net Operating Loss and Year-end Cash CARLSBAD, Calif., Feb. 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2013 financial results and reviewed the highlights of the year. Isis ended the year in a strong financial position and outperformed both its pro forma net operating loss (NOL) guidance and its cash guidance for the year. For the year ended December 31, 2013, Isis had an NOL of $40.2 million compared to...

2014-02-27 12:25:04

The mobile wallet landscape will undergo more change and innovation in the next two years than it has since its inception. In an already crowded marketplace with no single vendor leading the charge, Yankee Group identifies which providers have the long-term vision to succeed. BOSTON, Feb. 27, 2014 /PRNewswire/ -- The U.S. mobile payment landscape is currently in a state of flux: Although two-thirds of consumers are interested in learning more about transitioning to a mobile wallet platform,...

2014-02-26 12:30:37

LONDON, Feb. 26, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Consumer Payments Competitor Tracker The global consumer payments market is a highly dynamic and competitive space, which means that it is crucially important to stay on top of key developments. Datamonitor's Global Consumer Payments Competitor Tracker does just that, providing expert analysis and opinion on the key strategic moves of leading competitors in the consumer payments...

2014-02-25 08:31:09

CARLSBAD, Calif., Feb. 25, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Cowen and Company 34(th) Annual Health Care Conference on Tuesday, March 4, 2014 at 8:40 a.m. ET in Boston, MA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...

2014-02-21 16:23:09

On track to initiate Phase 3 study in infants with SMA in the middle of this year CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMN(Rx) in infants with spinal muscular atrophy (SMA). To date, all four infants in the 6 mg cohort have been in the study for over six months and are now approximately nine and a half to 16 months in age with an average age...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.